The Challenge of Anticoagulation: Getting Research Into Practice

Applying Innovation in Clinical Practice – Interactive Discussion

Activity Details
  • Credit Amounts:
    • CME: 1.00
    • Other: 1.00
  • Cost: Free
  • Release: May 3, 2017
  • Expires: May 2, 2020
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    ( Ratings)

Faculty

Giancarlo Agnelli Giancarlo Agnelli, MD
Professor, Internal Medicine
University of Perugia
Director, Internal and Cardiovascular Medicine and Stroke-Unit
University Hospital
Perugia, Italy

Kenneth A.  Bauer Kenneth A. Bauer, MD
Professor, Medicine
Harvard Medical School
Chief, Hematology Section
VA Boston Healthcare System
Director, Thrombosis Clinical Research
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Sylvia Haas Sylvia Haas, MD, PhD
Emeritus Professor, Medicine
Haemostasis and Thrombosis Research Group
Institute for Experimental Oncology and Therapy Research
Technical University of Munich
Munich, Germany

Needs Statement

Selection and duration of appropriate therapy for venous thromboembolism (VTE) can be improved in clinical practice. Physicians remain reluctant to prescribe anticoagulant (AC) prophylaxis in a large proportion of the population at risk for thromboembolic stroke. 

Risk factors for bleeding in patients receiving thromboprophylaxis must be recognized by the treating physician. The management of VTE frequently carries significant clinical challenges.

There is a need for improving the perception of strategies in prevention of thromboembolic stroke and concern about bleeding complications, especially among the elderly. The weighing of benefits of treatment against the risk of bleeding in thromboprophylaxis is important for patient outcome.

Target Audience

Health care professionals who are faced with challenges of anticoagulation treatment including the management of patients with VTE and/or patients with atrial fibrillation. These include practicing cardiologists, hematologists/oncologists, and geriatricians as well as specialists in Emergency Medicine, Internal Medicine, and all other subspecialist clinicians interested in anticoagulant therapy.

Objectives

Upon completion of this educational activity, participants will be able to:

  • Discuss the clinical factors that impact the choice of treatment for ischaemic stroke in an AF patient on prior warfarin
  • Evaluate the risk benefits of secondary stroke prevention with anticoagulants based on the evidence
  • Develop a management plan for restarting anticoagulant treatment (when and how)
  • Utilize clinical practice guidelines in the diagnosis and treatment of cancer-associated thrombosis (CAT)
  • Select an appropriate anticoagulant treatment regimen for a patient with CAT
  • Reinforce the need for appropriate perioperative care for patients with CAT
  • Discuss the need for ongoing/long-term anticoagulation
  • Utilize clinical practice guidelines in the diagnosis and treatment of VTE (DVT & PE)
  • Select appropriate anticoagulant treatment regimen for VTE patient with major bleeding complications (Parental anticoagulation vs NOACs)
  • Manage active bleeding in patients treated with conventional anticoagulants and NOACs
  • Discuss the role of NOACs in the treatment of VTE patients with bleeding

Accreditation

CME
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Kentucky College of Medicine, and Thrombosis Research Institute. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

ACGME Competencies

  • Patient care
  • Medical knowledge
  • Practice-based learning and improvement

Other
UK Healthcare CECentral certifies this activity for 1.00 hour of participation.

Faculty Disclosure

Giancarlo Agnelli, MD, (Speaker) has relevant financial relationships with commercial interests as follows:
Janssen, BMS, Instrumentation Laboratory - Consultant, Expert Testimony, Consultant Fee

Kenneth A. Bauer, MD, (Speaker) has relevant financial relationships with commercial interests as follows:
Janssen, BMS, Instrumentation Laboratory - Consultant, Expert Testimony, Consultant Fee

Christopher B. Granger, MD, (Planner) has relevant financial relationships with commercial interests as follows:
Armetheon - Principal Investigator, Research Support, Salary Support
AstraZeneca - Principal Investigator, Consultant & Other Services, Research Support, Consulting Fee
Bayer - Principal Investigator, Consultant & Other Services, Salary Support, Consulting Fee
Boehringer Ingelheim - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Bristol Myers Squibb - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Eli Lilly - Consultant & Other Services, Consulting Fee
Daiichi Sankyo - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
FDA - Principal Investigator, Research Support
Gilead - Consultant & Other Services, Consulting Fee
Glaxo SmithKline - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Hoffman-La Roche - Consultant & Other Services, Consulting Fee
Janssen Pharmaceuticals - Principal Investigator, Research Support
The Medicines Company - Principal Investigator, Consultant & Other Services, Research Support, Salary Support, Consulting Fee
Medtronic Foundation - Principal Investigator, Research Support, Salary Support

Sylvia Haas, MD, (Speaker) has relevant financial relationships with commercial interests as follows:
Aspen, Bayer, BMS, Daiichi Sankyo, Pfizer, and Sanofi - Consultant, Expert Testimony, Speakers Bureau, Consultant Fee, Honoraria

Lord Ajay Kakkar, BSc, MBBS, PhD, FRCS, (Planner) has relevant financial relationships with commercial interests as follows:
Aspen Pharma, Bayer Healthcare, Boehringer Ingelheim Pharma, Daiichi Sankyo Europe, Sanofi SA - Consultant, Expert Testimony, Principal Investigator, Consultant Fee, Research Support, Honoraria

No other planners or reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

This activity is jointly provided by the University of Kentucky and Thrombosis Research Institute.

Supported by an unrestricted educational grant from Bayer.

FRONTLINE 2 Survey

The Fundamental Research in Oncology and Thrombosis (FRONTLINE 2) Survey is designed to evaluate how clinicians perceive the risk of venous thromboembolism in cancer patients and to provide insight into current strategies for thromboprophylaxis and management. It has been developed with the guidance of an international advisory board of experts in this field. This survey is coordinated by the Thrombosis Research Institute, London. It has been developed with the guidance of an international advisory board of experts in this field. All replies will be treated in the strictest confidence. The survey is split into 5 Sections (A-E) and will take approximately 20 - 30 minutes to complete.

To complete the survey, visit http://frontline2.tri-london.ac.uk/

CE Content Concerns

Policy

Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504

Procedures

  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.